Menno van Nimwegen

Erasmus MC — Netherlands

Medicine · Health Sciences

35h-index6.9kcitations82works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Asthma and respiratory diseases(19), Immune Cell Function and Interaction(18), IL-33, ST2, and ILC Pathways(15), Cancer Immunotherapy and Biomarkers(14), Immunotherapy and Immune Responses(13)

Publications82 total

Evidence for altered immune-structural cell crosstalk in cystic fibrosis revealed by single cell transcriptomics
Journal of Cystic Fibrosis·2025· 6 citedOpen Access
Aberrant characteristics of peripheral blood innate lymphoid cells in COPD, independent of smoking history
ERJ Open Research·2024· 4 citedOpen Access
Type-2 CD8+ T-cell formation relies on interleukin-33 and is linked to asthma exacerbations
Nature Communications·2023· 37 citedOpen Access
WS14.06 Single cell RNA sequencing of lung biopsies reveals altered immune-structural cell crosstalk in cystic fibrosis
Journal of Cystic Fibrosis·2023Open Access
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
Science Immunology·2023· 93 citedOpen Access
Supplementary Table 1 from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023Open Access
Data from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023Open Access
Supplementary Figure from Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy
2023Open Access
Supplementary Figure from Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy
2023Open Access
Data from Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy
2023Open Access
Data from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023Open Access
Supplementary Table 1 from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023Open Access
Supplementary Figures S1 through S7 from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023Open Access
Supplementary Figures S1 through S7 from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023Open Access
Supplemental Figure Legends from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023Open Access
Data from Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy
2023Open Access
Supplemental Figure Legends from Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy
2023Open Access
Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy
Molecular Cancer Therapeutics·2022· 8 citedOpen Access
Peripheral Blood T Cells of Patients with IPAH Have a Reduced Cytokine-Producing Capacity
International Journal of Molecular Sciences·2022· 23 citedOpen Access
Late Breaking Abstract - Peripheral T-cells and their cytokine production in Chronic Thromboembolic Pulmonary Hypertension
2021
page 1 of 5Next →

Frequent Co-authors

Rudi W. Hendriks(35), Mirjam Kool(21), Henk C. Hoogsteden(18), Bart N. Lambrecht(18), Alex KleinJan(16), Hamida Hammad(13), Marjolein J. W. de Bruijn(13), Monique Willart(10), Joachim G.J.V. Aerts(10), Ingrid M. Bergen(10), Melanie Lukkes(9), Ralph Stadhouders(8), Louis Boon(7), Heleen Vroman(7), Femke Muskens(6), Bernt van den Blink(6), Gert‐Jan Braunstahl(6), Floris Dammeijer(5), Thorbald van Hall(5), Geertje M. de Boer(5)